Multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

Annals of Oncology

Volumn 24, Issue 9, 2013, Pages 2396-2402

  Melichar Prof , Bohuslav ^a   Bracarda, S ^b   Matveev, V ^c   Alekseev, B ^d   Ivanov, S ^e   Zyryanov, A ^f   Janciauskiene, R ^g   Fernebro, E ^h   Mulders, P ⁱ   Osborne, S ^j   Jethwa, S ^j   Mickisch, G ^k   Gore, M ^l   Van Moorselaar, R J A ^m   Staehler, M ⁿ   Magne, N ^o   Bellmunt, J ^p,q  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b Epilepsy Center   (Italy)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d Clinical Oncology Research Institute   (Russian Federation)

^e Ministry of Health of the Russian Federation   (Russian Federation)

^f Sverdlovsk District Clinical Hospital #1   (Russian Federation)

^g LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^h Vaxjo Hospital   (Sweden)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k Center of Operative Urology Bremen   (Germany)

^l Royal Marsden   (United Kingdom)

^m VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^o Institut de Cancerologie de la Loire   (France)

^p HARVARD MEDICAL SCHOOL   (United States)

^q HOSPITAL DEL MAR   (Spain)

more..

Author keywords

Angiogenesis; Bevacizumab; Immunotherapy; Interferon; Renal cell carcinoma; VEGF

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB;

ADULT; AGED; ANEURYSM RUPTURE; ANOREXIA; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DIGESTIVE SYSTEM PERFORATION; DRUG CHOICE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEART ARREST; HEART ATRIUM FIBRILLATION; HEMOPTYSIS; HUMAN; KIDNEY METASTASIS; LIVER FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS; BEVACIZUMAB; IMMUNOTHERAPY; INTERFERON; RENAL CELL CARCINOMA; VEGF;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84883331795     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt228     Document Type: Article

References (24)

1. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin N Am 1993; 20: 303-321.
2. Tannir NM, Thall PF, Ng CS et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008; 180(3): 867-872.
3. Richey SL, Ng C, Lim ZD, et al. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2011; 29(8): e203-e205.
4. Pyrhonen S, Salminen E, Ruutu M, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-2867.
5. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-17.
6. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
8. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1280-1289.
9. Hudes G, Carducci M, Tomczak P, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
10. Tannir NM, Cohen L, Wang X, et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006; 107: 2254-2261.
11. Conter HJ, Wood CG, Matin SF, et al. Ten-year follow-up of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with interferon alfa-2b (IFN) as first-line therapy: results from a randomized trial. J Clin Oncol 2013; 31 (suppl 6; abstr 365).
12. Escudier B, Pluzanska A, Koralewski P, et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
13. Bracarda S, Bellmunt J, Melichar B, et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon- α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int 2011; 107: 214-219.
14. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143.
15. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28: 2144-2150.
16. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alphα2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-1476.
17. Kirkwood JM, Harris JE, Vera R, et al. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res 1985; 45: 863-871.
18. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 234-243.
19. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46: 439-448.
20. Wu S, Kim C, Baer L, et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010; 21: 1381-1389.
21. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
22. Motzer R, Nosov D, Eisen I, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 2012; 30: 277s (Abstr 4501).
23. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 2003; 102: 442-448.
24. Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011; 12: 673-680.